VelaVigo is a leading biotech company specializing in the discovery and development of multispecific antibodies and ADCs. Backed by a highly efficient drug discovery platform and strong capabilities in translational medicine, CMC, and early clinical development, VelaVigo has built a robust pipeline of over ten FIC/BIC multispecific antibodies and ADC candidates, with a strategic focus on oncology and autoimmune diseases.


Since its inception in 2021, VelaVigo has completed three major financing rounds with a total of $160 million funding. VelaVigo has successfully established a sustainable “BD+VC” model. In November 2024, the company entered into an out-licensing agreement with U.S.-based Avenzo valued at $800 million, with a $50 million upfront and near-term milestone payment. In April 2025, VelaVigo signed a second out-licensing deal with the U.S. company Ollin, valued at $440 million. These landmark partnerships highlight the technological strength and commercial value of VelaVigo’s innovative pipeline.


In 2025, VelaVigo’s core R&D programs advanced into clinical development in both China and the U.S. The company will continue to expand strategic partnerships across technology platforms, clinical development, and capital markets to maximize R&D efficiency and return on investment.

VelaVigo

Org chart

Teams

Offices